In the near future, management of MIDD is likely to be facilitated through the definition of international response criteria and the use of novel anti-plasma cell agents, particularly anti-CD38 monoclonal antibodies in which efficacy and good tolerance profile have been established in multiple myeloma. Here, CD38 is linked to plasma cell myeloma.